Page 1,470«..1020..1,4691,4701,4711,472..1,4801,490..»

Pierre Coulombe, Ph.D. to lead UM Department of Cell & Developmental Biology – University of Michigan Health System News (press release)

Posted: June 17, 2017 at 9:42 am

ANN ARBOR, MI One of the oldest departments at the University of Michigan is about to get a new leader. The U-M Board of Regents today approved the appointment of Pierre A. Coulombe, Ph.D., to lead the Department of Cell and Developmental Biology in the Medical School.

Coulombe will become chair on August 1, and lead one of the nine basic science departments of Michigan Medicine, U-Ms academic medical center. The departments researchers study how structure governs function in cells and tissues throughout the body, and how complex arrays of signals are integrated to foster the proper development of tissues and organs. They also study stem cells, including embryonic stem cells, and train undergraduate, graduate and medical students in cell biology.

The department traces its roots back to 1854, soon after the founding of the Medical School, when it was known as the Department of Anatomy.

Coulombe comes to Michigan from Johns Hopkins University, where he chaired the Department of Biochemistry and Molecular Biology in the Bloomberg School of Public Health for nine years, and held the E.V. McCollum professorship as well as several joint appointments in the School of Medicine. At Hopkins, Coulombe was noted for recruiting and nurturing junior faculty members to success, and developing robust training programs for graduate students and post-doctoral fellows. He was also instrumental in addressing the departments infrastructure needs.

To me, cell and developmental biology are critically important endeavors as one seeks to translate the wealth of knowledge acquired in biochemistry and molecular biology, along with the power of imaging techniques, into a better understanding of how organs and tissues form, and operate, under normal and disease conditions, he says. This knowledge is also important for developing novel therapies for human disease. U-M already is a formidable institution, and otherwise is making a substantial investment into biomedical research. Therefore, I am absolutely thrilled about the opportunity to lead Cell & Developmental Biology, and team up with my new colleagues in the department and at U-M, to fulfill this potential.

In addition to his appointment in Cell & Developmental Biology, Coulombe will have a joint appointment in the U-M Department of Dermatology. His research focuses on understanding how keratin proteins and the nanoscale filaments they form foster an optimal architecture and function in skin and related epithelia, and how disruption of these processes result in diseases ranging from inherited conditions to cancer.

A native of Montral, Qubec, Coulombe earned his undergraduate degree from the Universit du Qubec Montral and his Ph.D. in Pharmacology from Universit de Montral. He completed his postdoctoral fellowship in the Department of Molecular Genetics and Cell Biology & Howard Hughes Medical Institute at the University of Chicago before joining Johns Hopkins School of Medicine in 1992. He is the author of more than 140 peer-reviewed publications and one book, holds one patent, and has received multiple awards in recognition of his research and teaching endeavors.

For more about the U-M Department of Cell and Developmental Biology, visit https://medicine.umich.edu/dept/cell-developmental-biology.

Continued here:
Pierre Coulombe, Ph.D. to lead UM Department of Cell & Developmental Biology - University of Michigan Health System News (press release)

Posted in Cell Medicine | Comments Off on Pierre Coulombe, Ph.D. to lead UM Department of Cell & Developmental Biology – University of Michigan Health System News (press release)

On the cusp of payoffs for patients, stem cell therapy faces threat from unregulated clinics – STAT

Posted: June 17, 2017 at 9:41 am

TV documentary on pain treatment funded by doctor with

TV documentary on pain treatment funded by doctor with industry ties

For some chronic pain patients, without opioids, life would

For some chronic pain patients, without opioids, life would be torture

Googles bold bid to transform medicine hits turbulence under

Googles bold bid to transform medicine hits turbulence under a divisive CEO

At first meeting of Trumps opioid commission, health advocates

At first meeting of Trumps opioid commission, health advocates plead for Medicaid spending

This bill would reinstate a controversial drug discount for

This bill would reinstate a controversial drug discount for some hospitals

Up and down the ladder: The latest comings and

Up and down the ladder: The latest comings and goings

See original here:
On the cusp of payoffs for patients, stem cell therapy faces threat from unregulated clinics - STAT

Posted in Cell Therapy | Comments Off on On the cusp of payoffs for patients, stem cell therapy faces threat from unregulated clinics – STAT

Broccoli Could Be a Secret Weapon Against Diabetes, Say Scientists – ScienceAlert

Posted: June 17, 2017 at 9:41 am

Broccoli contains an ingredient that can help those with type 2 diabetes control their blood sugar level, according to a new study potentially providing a much-needed treatment option for millions.

A chemical in cruciferous vegetables like broccoli and sprouts calledsulforaphaneis thought to be responsible,having been shown to lower glucose levels in earlier lab experiments on diabetic rats.

To identify suitable compounds to examine, researchers used computer models to identify gene expression changes linked with type 2 diabetes, and then sift through thousands of chemicals that might reverse these changes.

"We're very excited about the effects we've seen and are eager to bring the extract to patients," one of the researchers, Anders Rosengren of the University of Gothenburg in Sweden, told Andy Coghlan at New Scientist.

"We saw a reduction of glucose of about 10 per cent, which is sufficient to reduce complications in the eyes, kidneys and blood."

That 10 percent average reduction was across a sample of 97 human volunteers taking part in a 12-week randomised, placebo-controlled trial. The participants who were obese and who had higher baseline glucose levels to begin with benefitted the most.

The dose was the equivalent of around 5 kilograms (11 pounds) of broccoli daily a fair few platefuls but the researchers say it could be adapted into a powder to add to food or drinks.

It's important to note that all but three of those taking part in the trial continued to take metformin, a drug already used to improve blood sugar regulation in people with diabetes.

However, the researchers think sulforaphane could eventually replace metformin for some patients up to 15 percent of those with diabetes can't take metformin because of the associated risks of kidney damage.

The two chemicals take different approaches: sulforaphane suppresses the enzymes in the liver that stimulate glucose production, whereas metformin makes cells more sensitive to insulin, taking more glucose out of the bloodstream.

With more than 29 million people having type 2 diabetes in the US alone, and that number on the rise, any kind of help is going to be very welcome.

Before the human trial, the researchers also found sulforaphane was able to reduce glucose production in liver cells grown in a lab, and shift liver gene expression away from an abnormal, diseased state in diabetic rats.

Larger and more detailed studies are required before the drug can get approved for regular treatments though, and until then it's probably wise to keep your vegetable intake to a normal, healthy level.

"More research is needed to see if this repurposed drug can be used to treat Type 2 diabetes, as it was only tested in a small number of people and only helped a subset of those who are taking it," Elizabeth Robertson from Diabetes UK, who wasn't involved in the research, told New Scientist.

"For now, we recommend that people continue with the treatment prescribed by their healthcare team."

The findings have been published in Science Translational Medicine.

Continued here:
Broccoli Could Be a Secret Weapon Against Diabetes, Say Scientists - ScienceAlert

Posted in Diabetes | Comments Off on Broccoli Could Be a Secret Weapon Against Diabetes, Say Scientists – ScienceAlert

Diabetes camp educates, entertains – Hastings Tribune

Posted: June 17, 2017 at 9:41 am

Sometimes its good to just be one of the gang.

This is certainly true for those dealing with Type 1 diabetes. And thats why Camp Hot Shots has become a favorite get-away destination for hundreds of youngsters ages 6-12 in central Nebraska since 2001.

Founded by Mary Lanning Heathcare and presented this year in partnership with Grace United Methodist Church, the two-day camp gives youngsters dealing with the disease a chance to bond with fellow diabetics without having to address those intrusive questions so often posed by their well-meaning but unmindful peers.

DeAnn Carpenter, program coordinator for Mary Lannings diabetes program, said the camp which is funded in part through donations from area organizations combines diabetes education and a host of fun activities to create an experience many campers have come to look forward to year after year.

More than 20 area children are taking part in this years long list of camp activities, which include: Boat rides and water play at Lake Hastings and Aquacourt Water Park, YMCA play, string art, balloon artist/magician Poppin Penelope, taekwondo, and more.

Its just a time for kids who have Type 1 diabetes to come together and realize theyre not alone, Carpenter said. A lot of them are the only ones in their school system or community who have Type 1 diabetes and maybe feel a little alone, having to take care of themselves. Its a time to bond and interact with people who have the same diagnosis as them.

For many campers, the camp has become an annual tradition, a place to bond with new found friends over shared activities. In some instances, it may be the only contact they have with their fellow diabetic companions each year.

For Braden Benjamin, 12, of Friend, this year marks his seventh go-around in the camp.

I like coming to the lake and swimming and tubing with my friends, he said. I get to see other diabetics that Im not around very often. I know most of them, but there are a few new ones every now and then.

I also like going to the YMCA. They have a bunch of different activities, like tennis and racquetball. You can go to the batting cage, and theres a pool there, too.

But its the camaraderie with fellow diabetics that makes the camp experience special to himself and fellow participants, he said.

The camp allows me to talk to other diabetics that I dont get to see very often. Its just nice to be around other people who share the disease that you have and know what it feels like. I hope to make more friends at the camp this year and get better at taking care of my diabetes. If my blood sugars are good I can pretty much do anything if I treat it beforehand.

Kordell Lovitt, 13, of Chapel, is attending the camp for the fourth straight year. Like most all of his fellow campers, he considers the lake activities the high water point of the two-day outing.

Im just swimming and having fun with my friends that I dont see a lot, he said. We talk about how we take care of our diabetes and how we treat our lows and highs. It (diabetes) is kind of stressful, but sometimes I just get over it.

And camp is a big reason for that, he said.

The others tell me what I dont do right and that I can do a better job of it, he said. I check on my blood sugars often here to keep them in range.

Having to explain himself and his limitations to non-diabetics day in and day out makes coming to camp seem even more of a getaway experience each year.

When people ask me, Why do you have to do this? its kind of weird and awkward, he said. Here, I dont have to tell them anything. I just want to have fun and pay attention to my diabetes.

Fourth-time camper Emmilly Berglund, 12, of Shelton said she felt right at home navigating the lakeside waters with friends of a feather.

I just like to come and see the other kids and talk to them about how everything is, she said. Its just enjoyable and relaxing to hang around other kids who have it (Type 1 diabetes). Im looking forward to the new activities they have this year like string art and going to the water park and learning new things.

Lee Wigert, 65, is a teacher at Hastings College and pastor of United Methodist churches in Juniata, Holstein and Kenesaw.

He, along with his wife, Diane, and son, Nate, 32, who has diabetes, have been donating their time giving boat and jet ski rides and sharing their back yard abutting Lake Hastings for the past decade.

Its just amazing the bonding experience that these children have, he said. The kids come back year after year and call you by name and you remember them. I spend about three days getting the house ready and tubes and trampoline blown up.

We make sure everybody gets on the boat. What they take away from this is that they know the adults care for them and are here to help them out.

See the rest here:
Diabetes camp educates, entertains - Hastings Tribune

Posted in Diabetes | Comments Off on Diabetes camp educates, entertains – Hastings Tribune

Expand coverage for diabetes treatment | Sally Hillerich Galla – The Courier-Journal

Posted: June 17, 2017 at 9:40 am

Sally Hillerich Galla, Guest Contributor 3:13 p.m. ET June 15, 2017

Measuring blood sugar(Photo: Maya23K, Getty Images/iStockphoto)

It might be old-fashioned, but as a young child growing up in Kentucky, I was taught never to reveal my age. Yet to understand my story, you have to start with a number: Im 65, and Im incredibly fortunate to be alive.

At the age of 24, my doctor gave me six months to live, along with one last hope: an emergency surgery to treat the endometriosis which was threatening my life. Thankfully, that surgery was a success.

But my medical journey was just beginning.

In the weeks after my surgery, I lost 30 pounds, and my vision was getting increasingly blurry. A trip back to my doctor confirmed a new, equally troubling and unrelated diagnosis: Type-1 diabetes. At the time, the outlook for Type-1 patients was grim.

Like every person with Type-1 Diabetes, not a day goes by that I dont spend thinking about and treating my disease. But there are some risk factors beyond our control, notably that Medicare, unlike nearly every private insurance plan, wont pay for some treatments that helpus stay healthy.

To start, it helps to understand that Type-1 Diabetes keeps your pancreas from producing insulin, so those of us living with the disease must inject the right amount of insulin ourselves, using everything from needles to traditional insulin pumps. Youve probably seen these pumps; a patch is connected by tubes to a device clipped to your belt or placed in your pocket.

More: New health bill even worse threat for Kentuckians | Comment

More: Poverty, obesity fuel Ky's diabetes epidemic

More: Help list: Learn to avoid or manage diabetes

Devices like this come with significant drawbacks. They cant get wet, and patients with neuropathy and arthritis have a hard time connecting and re-connecting the tubes multiple times a day. However, they do have one major benefit: theyre covered by Medicare.

The device I use called an Omnipod isnt.

My Omnipod is a wireless pump; a small pod that can be worn nearly anywhere and is connected wirelessly to a device about the size of a cell phone, which doesnt have to be clipped to your clothing. Instead, it just has to be close by.

And this is where that bureaucratic thinking comes in. All other insulin pumps are paid for under Medicare Part B because theyre considered durable medical equipment.

But the Omnipod isnt.

Thats because the Omnipod is different. Each of the pods lasts three days. Once its supply of insulin is used up, you replace it with another. You keep the cell phone-sized transmitter, which connects wirelessly to each new pod. Yet even though it has been approved by the FDA for 12 years, Medicare still wont cover it.

Medicares non-coverage policy is in conflict with Congresss intent, which was to promote medical innovation. Back in 2003, they passed the Medicare Modernization Act, which made it clear: new technologies not covered under Part B should be covered under Part D, which covers medicines. Medicare hasnt used that authority to cover the Omnipod either. But it should.

Because Omnipod isnt covered under Medicare, the Federal government is forcing seniors like me to abandon the treatment we need.

Now Im fortunate: After paying out of pocket since I turned 65, I recently found out that my Express Scripts Medicare Advantage plan has decided to stop mirroring Medicares policy. Thanks to that decision, I will get the coverage I need. But millions of people arent as fortunate they rely on other Medicare and Medicare Advantage plans where Omnipod still isnt covered.

Every major diabetes patient and medical advocacy group agrees: There should be no reason why the Omnipod remains the only FDA-approved insulin pump not covered by Medicare. Theyve urged the Centers for Medicare and Medicaid Services to cover the Omnipod. And Im urging them now, too.

Medicare should cover Omnipod, because it is a critical part of my medical plan. I shouldnt be forced to lose it just because Ive turned 65and neither should any other senior.

A small business owner, Sally Hillerich Galla is a 40-year veteran of the health insurance industry who lives in Eastern Jefferson County with her husband, Patrick.

Read or Share this story: http://www.courier-journal.com/story/opinion/contributors/2017/06/15/expand-coverage-diabetes-treatment-sally-hillerich-galla/399244001/

Originally posted here:
Expand coverage for diabetes treatment | Sally Hillerich Galla - The Courier-Journal

Posted in Diabetes | Comments Off on Expand coverage for diabetes treatment | Sally Hillerich Galla – The Courier-Journal

Arizona Supreme Court Clears Way For Adoption of American Indian Child by Non-Native Parents – Reason (blog)

Posted: June 15, 2017 at 9:43 pm

Glassholic/FoterIn considering the rights of Native American foster children, should the emphasis be placed on their status as Native Americans or as children?

The Arizona Supreme Court chose the latter, clearing a non-native couple to adopt their foster daughter over objections of a local Indian tribe.

The court's ruling is a challenge to the controversial 1978 Indian Child Welfare Act (ICWA). Proponents say the act is essential to keep Native American communities together. Critics contend it establishes a racially discriminatory system that negatively affects the safety and welfare of Indian children.

At the time of ICWA's passage, removal of Native American children from their homes was "truly an epidemic that threatened native American children and their families," David E. Simmons, Government Affairs Director for the National Indian Child Welfare Association, tells Reason.

ICWA sought to stem this so-called epidemic by conferring upon sovereign tribal nations the right to be involved in the adoption process of their citizens. Tribes were free to employ "community-based services and community-based knowledge" in deciding on the placement of children.

ICWA, however, has little do with the legal or cultural attachment of a child to a tribal community, and everything to do with a biological attachment to a racial group, Timothy Sandefur, Vice President for Litigation at the Goldwater Institute, says.

The Goldwater Institute has intervened in a number of ICWA cases including this most recent one in Arizona.

"If you have the right blood cells in your veins, then ICWA applies a separate and substandard set of rules that makes it harder to protect you from abuse and neglect, and harder to find you an adoptive home," Sanderfur says.

In 2014 an infant identified as A.D. in court documents was born to a member of the Gila River Indian Community. Both A.D. and her mother tested positive for amphetamines and opiates and the Arizona Department of Child Services ordered the child placed her current non-native foster parents.

Sarah and Jeremy H., according to the court documents, moved to adopt A.D in Arizona state court in June 2015. But despite repeated failures to find a suitable tribal family for A.D., the Gila River Indian Community blocked the adoption claiming tribal court jurisdiction through ICWA.

The Arizona Supreme Court unanimously rejected the Gila River Indian Community's argument, but broader concerns about the authority of ICWA remain. The act's departure from standard adoption law has exposed Native American children to parents who have systemically physically and sexually abused them, Sandefur says.

Laws that govern foster care for children of all other races, by contrast, require "reasonable efforts" be made to reunite children and parents, but draw the line at trying to return kids to homes where they have experienced "systemic abuse."

One example was the case of Shayla H. Under the ICWA requirement she was returned to a sexually abusive fathera member of the Rosebud Sioux Tribeonly to be removed a month later after further incidences of sexual abuse.

In Minnesota, three siblings were removed and returned to their alcoholic parents so many times child services workers stopped counting at 500.

At the behest of the North Dakota Spirit Lake tribe, Laurynn Whiteshield and her twin sister, were taken from a non-native foster family and placed with her Native American grandfather and a step-grandmother charged eight total with child abuse.

A little more than a month later the step-grandmother was charged with murdering Laurynn Whiteshield.

The most recent Arizona case, Sandefur says, was a narrow victory decided on more technical and procedural grounds. The Goldwater Institute has brought a class action suit in federal court on behalf of off-reservation Indian children subject to ICWA to broaden its impact.

The case is currently before the Ninth Circuit Court of Appeal.

The goal, Sandefur says, is not to strike down the entire law or undermine the authority of Indian tribes.

"It [ICWA] needs to be amended," he says, "with the principle in mind that all Indian children are citizens of the United States entitled to equal protection of the laws, and that means no separate rules based on biology."

More:
Arizona Supreme Court Clears Way For Adoption of American Indian Child by Non-Native Parents - Reason (blog)

Posted in Arizona Stem Cells | Comments Off on Arizona Supreme Court Clears Way For Adoption of American Indian Child by Non-Native Parents – Reason (blog)

This Biotechnology Company Wants to Reanimate the Brain-Dead – TrendinTech

Posted: June 15, 2017 at 9:42 pm

Ira Pastor, CEO of Bioquark, a Philadelphia-based biotechnology company, believes we will on day be able to reset the brain of patients declared brain-dead using a series of stem cell injections and nerve stimulations.

Until recently, death was medically defined as a loss of heart and lung function but as medical technology has advanced so has the qualifications. Now, since both heartbeat and breathing functions can be performed for a patient by machine, death is almost universally declared when there is a loss of activity in the brain stem. However, Pastor does think that this loss of brain function is as irreversible as weve come expect.

Initially, Bioquark was slated to start trials for the procedure last year in India but, due to strong opposition by the Indian Council of Medical Research, those studies were canceled. Nevertheless, Ira Pastor and his collaborator Himanshu Bansal, an orthopedic surgeon, remain undaunted and have announced a new series of test to happen soon in a nameless South American country.

Although they have not released the details of the revolutionary procedure, we can gather a general idea of their plan to reanimate the brain-dead from the papers regarding their original canceled trial.

Originally, the researchers wanted brain-dead subjects between the ages of 12 and 65. Ideally, the cause of the brain damage would be due to traumatic injury. Scientists would look at MRIs to determine eligibility, then brain cells would be harvested from the patients blood. After the stem cells are injected, the patients would get another injection, this time peptides, directly to the spinal column. The series of injections is followed by two weeks of nerve stimulation, specifically the median nerve, by lasers, which Bioquark thinks is the key to reversing brain death.

Bioquark has not clarified how it intends to obtain consent from technically dead patients but in spite of the controversy, this study is not alone. The work at Bioquark is part of a larger program concerning neuro-reanimation and regeneration called ReAnima.

Pastor, who also serves on the advisory board for the project, told the Daily Mail: The mission of the ReAnima Project is to focus on clinical research in the state of brain death, or irreversible coma, in subjects who have recently met the Uniform Determination of Death Act criteria, but who are still on cardio-pulmonary or trophic support a classification in many countries around the world known as a living cadaver.

More News to Read

comments

Follow this link:
This Biotechnology Company Wants to Reanimate the Brain-Dead - TrendinTech

Posted in Biotechnology | Comments Off on This Biotechnology Company Wants to Reanimate the Brain-Dead – TrendinTech

Biotechnology expert proposed for top Chinese University of Hong Kong post – South China Morning Post

Posted: June 15, 2017 at 9:42 pm

An internationally renowned biotechnology scientist, Professor Rocky Tuan Sung-chi, has been recommended to succeed Joseph Sung Jao-yiu as Chinese University vice-chancellor.

Born in Hong Kong and educated in the United States, Tuan is currently working at the University of Pittsburgh as director of the institutions cellular and molecular engineering lab, executive vice-chairman of the Department of Orthopaedic Surgery and a professor in the Department of Bioengineering.

He has been serving as a distinguished visiting professor and director of the Institute for Tissue Engineering and Regenerative Medicine at Chinese University.

The institutions council said on Thursday that it would recommend Tuan to be the next vice-chancellor. It will hold a consultation of up to six weeks with staff, students and alumni, but the universitys teachers association vowed to boycott it, saying the council had fooled it by saying it was not sure who the candidate was.

In May 2016, Tuan was one of the 10 Carnegie Science Award winners for his extensive experience in applying adult stem cells for tissue engineering and regenerative medicine.

Hes a good scientist, professionally speaking, with a major interest in bone and tendon regeneration, Professor Chan Wai-yee of the universitys School of Biomedical Sciences said. He used to chair the biology and medicine panel of the Research Grants Council so he should know better than others what improvements can be made to develop Hong Kongs scientific research.

I have high expectations of him. As a successful scholar who has worked for the Research Grants Council for so many years, he could at least reflect our wish for more funding and resources.

However, Professor Chan King-ming, president of the Chinese University Teachers Association, said he was angry about the announcement and that staff and students were being played by the universitys top administration, who two weeks ago told the association they were still not sure about the candidate.

Chan King-ming also said Tuan lacked outstanding academic status and administrative experience. Seldom were his papers published by top journals and he has never served at the level of deputy vice-chancellor or dean in any university, the biochemistry scholar said.

Read the original post:
Biotechnology expert proposed for top Chinese University of Hong Kong post - South China Morning Post

Posted in Biotechnology | Comments Off on Biotechnology expert proposed for top Chinese University of Hong Kong post – South China Morning Post

Vontobel Swiss Wealth Advisors AG Acquires 4956 Shares of iShares Nasdaq Biotechnology Index Fund (IBB) – The Cerbat Gem

Posted: June 15, 2017 at 9:42 pm

Vontobel Swiss Wealth Advisors AG Acquires 4956 Shares of iShares Nasdaq Biotechnology Index Fund (IBB)
The Cerbat Gem
iShares Nasdaq Biotechnology Index Fund logo Vontobel Swiss Wealth Advisors AG increased its position in shares of iShares Nasdaq Biotechnology Index Fund (NASDAQ:IBB) by 36.0% during the first quarter, according to its most recent 13F filing with the ...
Ken Stern & Associates Inc. Has $318000 Stake in iShares Nasdaq Biotechnology Index Fund (IBB)Stock Observer
iShares Nasdaq Biotechnology Index Fund - Receive News & Ratings DailyBBNS
The Traders Buy Large Volume of Put Options on iShares Nasdaq Biotechnology Index Fund (IBB)BangaloreWeekly

all 7 news articles »

Follow this link:
Vontobel Swiss Wealth Advisors AG Acquires 4956 Shares of iShares Nasdaq Biotechnology Index Fund (IBB) - The Cerbat Gem

Posted in Biotechnology | Comments Off on Vontobel Swiss Wealth Advisors AG Acquires 4956 Shares of iShares Nasdaq Biotechnology Index Fund (IBB) – The Cerbat Gem

Induced Cell Turnover: A proposed modality for in situ tissue regeneration & repair – Medical Xpress

Posted: June 15, 2017 at 9:41 pm

June 15, 2017 Credit: Biogerontology Research Foundation, Feinberg School of Medicine & Swammerdam Institute for Life Sciences

Thursday, July 15, 2017, London, UK: Scientists at the Biogerontology Research Foundation, Feinberg School of Medicine at Northwestern University and Swammerdam Institute of Life Sciences at the University of Amsterdam have published a paper on a proposed method of in situ tissue regeneration called Induced Cell Turnover (ICT) in the journal Human Gene Therapy. The proposed therapeutic modality would aim to coordinate the targeted ablation of endogenous cells with the administration of minimally-differentiated, hPSC-derived cells in a gradual and multi-phasic manner so as to extrinsically mediate the turnover and replacement of whole tissues and organs with stem-cell derived cells.

"One of the major hurdles limiting traditional cell therapies is low levels of engraftment and retention, which is caused in part by cells only being able to engraft at locations of existing cell loss, and by the fact that many of those vacancies have already become occupied by ECM and fibroblasts (i.e. scar tissue) by the time the cells are administered, long after the actual occurrence of cell loss. The crux underlying ICT is to coordinate endogenous cell ablation (i.e. induced apoptosis) with replacement cell administration so as to manually vacate niches for new cells to engraft, coordinating these two events in space and time so as to minimize the ability for sites of cell loss to become occupied by ECM and fibroblasts. This would be done in a gradual and multi-phasic manner so as to avoid acute tissue failure resulting from the transient absence of too many cells at any one time. While the notion of endogenous cell clearance prior to replacement cell administration has become routine for bone marrow transplants, it isn't really on the horizon of researchers and clinicians working with solid tissues, and this is something we'd like to change." said Franco Cortese, Deputy Director and Trustee of the Biogerontology Research Foundation, and lead author on the paper.

Cell-type and tissue-specific rates of induced turnover could be achieved using cell-type specific pro-apoptotic small molecule cocktails, peptide mimetics, and/or tissue-tropic AAV-delivered suicide genes driven by cell-type specific promoters. Because these sites of ablation would still be "fresh" when replacement cells are administered, the presumption is that the patterns of ablation will make administered cells more likely to engraft where they should, in freshly vacated niches where the signals promoting cell migration and engraftment are still active. By varying the dose of cell-type targeted ablative agents, cell type and tissue-specific rates of induced turnover could be achieved, allowing for the rate and spatial distribution of turnover to be tuned to the size of the tissue in order to avoid ablating too many cells at once and inadvertently inducing acute tissue failure.

"Cell therapies are limited by low levels of engraftment, and in principal their ability to improve clinical outcomes is limited by the fact that they can only engraft at locations of existing cell loss. Conversely, therapeutic tissue and organ engineering requires surgery, is more likely to introduce biochemical and mechanical abnormalities to tissue ultrastructure through the decellularization process, and is fundamentally incapable of replacing distributed tissues and structures with a high degree of interconnectivity to other tissues in the body. The aim of ICT is to form a bridge between these two main pillars to regenerative medicine, extending the efficacy of cell therapies beyond a patch for existing cell loss and accomplishing the aim of tissue and organ engineering (i.e. the replacement and regeneration of whole tissues and organs) while potentially remaining free of some of their present limitations." said Giovanni Santostasi, co-author on the paper and a researcher at the Feinberg School of Medicine, Northwestern University.

While future iterations of the therapy could use patient-derived cells, such as ESCs derived via somatic cell nuclear transfer (SCNT) or iPSCs derived from nuclear reprogramming, shorter-term applications would likely use existing stem cell lines immunologically matched to the patient via HLA matching. The authors contend that the cloning of adult organisms with normal lifespans from adult somatic cells testifies to the fact that adult cells can be rejuvenated and used to produce a sufficient quantity of daughter cells to replace the sum of cells constituting adult organisms, and that serial cloning experiments (in which this process is done iteratively, using an adult cell of each subsequent generation to derive the next) attests to this fact even more strongly.

"ICT could theoretically enable the controlled turnover and rejuvenation of aged tissues. The technique is particularly applicable to tissues that are not amenable to growth ex vivo and implantation (as with solid organs)such as the vascular, lymphatic, and nervous systems. The method relies upon targeted ablation of old, damaged and/or senescent cells, coupled with a titrated replacement with patient-derived semi-differentiated stem and progenitor cells. By gradually replacing the old cells with new cells, entire tissues can be replaced in situ. The body naturally turns over tissues, but not all tissues and perhaps not optimally. I am reminded of the quote attributed to Heraclitus: 'No man ever steps in the same river twice, for it's not the same river and he's not the same man.'" said Sebastian Aguiar, a coauthor on the paper and researcher at the Swammerdam Institute of Life Sciences, University of Amsterdam.

"Reversing aging in humans will require a multi-step approach at multiple levels of the organismal organization. In situ targeted ablation of the senescent cells and regeneration will be an important component of comprehensive anti-aging therapies." said Alex Zhavoronkov, Chief Science Officer of the Biogerontology Research Foundation.

The researchers originally proposed ICT in 2016 in the context of biomedical gerontology as a possible means of preventing and/or negating age-related phenotypic deviation for the purposes of healthspan extension, and in this new paper they refine the methodological underpinnings of the approach, take a closer look at potential complications and strategies for their deterrence, and analyze ICT in the context of regenerative medicine as an intervention for a broader range of conditions based on disease or dysfunction at the cellular and intercellular level, with potential utilities absent from traditional cell therapies and tissue/organ engineering, the two main pillars of regenerative medicine. The intervention is still very much conceptual, and any potential utilities over other therapeutic modalities within regenerative medicine would need to be verified via preclinical studies, but their hope is to stimulate further research at this interface between geroscience and regenerative medicine.

More information: Francesco Albert Bosco Cortese et al, Induced Cell Turnover: A novel therapeutic modality for in situ tissue regeneration, Human Gene Therapy (2017). DOI: 10.1089/hum.2016.167

Journal reference: Human Gene Therapy

Provided by: Biogerontology Research Foundation

Researchers at Karolinska Institutet in Sweden have obtained the first 3D snapshots of a sperm protein attached to a complementary egg coat protein at the beginning of fertilisation. The study, which reveals a common egg ...

As we bask in the summer heat, it is easy to take for granted that humans are also prepared for the cold of winter, with overcoats in the closet and home heating systems ready to be fired up as an added assurance against ...

Organs-on-Chips (Organ Chips) are emerging as powerful tools that allow researchers to study the physiology of human organs and tissues in ways not possible before. By mimicking normal blood flow, the mechanical microenvironment, ...

Monash University's Biomedicine Discovery Institute (BDI) researchers have collaboratively developed a therapeutic approach that dramatically promotes the growth of muscle mass, which could potentially prevent muscle wasting ...

As a molecular biologist, Kaori Noridomi gets an up-close view of the targets of her investigations. But when she began studying the molecular structures of a rarely diagnosed autoimmune disorder, myasthenia gravis, she decided ...

Researchers from Imperial College London and colleagues have found a potential way to target the receptors that specifically control appetite in mouse brains, potentially without causing other side effects.

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Go here to see the original:
Induced Cell Turnover: A proposed modality for in situ tissue regeneration & repair - Medical Xpress

Posted in Cell Medicine | Comments Off on Induced Cell Turnover: A proposed modality for in situ tissue regeneration & repair – Medical Xpress

Page 1,470«..1020..1,4691,4701,4711,472..1,4801,490..»